Correlation Between Acrivon Therapeutics, and Protalix Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Protalix Biotherapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Protalix Biotherapeutics.

Diversification Opportunities for Acrivon Therapeutics, and Protalix Biotherapeutics

-0.48

Correlation Coefficient

Acrivon Therapeutics,  Protalix Biotherapeutics

Very good diversification

The 3 months correlation between Acrivon and Protalix is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Protalix Biotherapeutics

Given the investment horizon of 90 days Acrivon Therapeutics, is expected to generate 1.76 times less return on investment than Protalix Biotherapeutics. In addition to that, Acrivon Therapeutics, is 1.51 times more volatile than Protalix Biotherapeutics. It trades about 0.01 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.04 per unit of volatility. If you would invest  117.00  in Protalix Biotherapeutics on August 30, 2024 and sell it today you would earn a total of  52.00  from holding Protalix Biotherapeutics or generate 44.44% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Protalix Biotherapeutics

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Protalix Biotherapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Acrivon Therapeutics, and Protalix Biotherapeutics

The main advantage of trading using opposite Acrivon Therapeutics, and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.

The idea behind Acrivon Therapeutics, Common and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.